Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients

7 Oct 1992

Abstract excerpt

BACKGROUND: ERCC1 and ERCC2 are human DNA repair genes that are associated with in vitro resistance to selected DNA-damaging agents. PURPOSE: Fresh tumor tissues from 26 patients with ovarian cancer were analyzed for the RNA levels of expression of these genes to determine possible clinical relevance. METHODS: Tumor tissues were harvested from patients immediately before they entered a cisplatin- or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Genetic factors in colorectal cancer
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 1433335
DOI: 10.1093/jnci/84.19.1512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer PatientsPMID 1433335Read ↗

Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related.Semantic proximity Read ↗

Clinicopathological and functional significance of XRCC1 expression in ovarian cancerSemantic proximity Read ↗

Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.Semantic proximity Read ↗

Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.Semantic proximity Read ↗

ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cellsSemantic proximity Read ↗

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.Semantic proximity Read ↗

ERCC1 and Clinical Resistance to Platinum-Based TherapySemantic proximity Read ↗

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian CancerSemantic proximity Read ↗

A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane ChemotherapySemantic proximity Read ↗

DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell linesSemantic proximity Read ↗

Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.